Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.

Solbeck, Sacha ; Meyer, Martin A S ; Johansson, Pär I ; Meyer, Anna Sina P ; Cotton, Bryan A ; Stensballe, Jakob ; Schött, Ulf LU and Ostrowski, Sisse R (2014) In International Journal of Cardiology 176(3). p.794-799
Abstract
Dabigatran etexilate, a pro-drug of a direct thrombin inhibitor, was approved a few years ago for non-valvular atrial fibrillation and deep venous thrombosis. Rapid monitoring of the dabigatran level is essential in trauma and bleeding patients but the traditional plasma-based assays may not sufficiently display the effect. Furthermore, no antidote exists and reversal of the anticoagulant effect is impossible or difficult. The present study investigated the in vitro effect of dabigatran on whole blood thromboelastography (TEG) and its reversal by recombinant activated factor VII and prothrombin complex concentrate.
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
International Journal of Cardiology
volume
176
issue
3
pages
794 - 799
publisher
Elsevier
external identifiers
  • pmid:25156858
  • wos:000343893300059
  • pmid:25156858
  • scopus:84908214306
ISSN
0167-5273
DOI
10.1016/j.ijcard.2014.07.084
project
Koagulation vid kirurgi och kritisk sjukdom
language
English
LU publication?
yes
id
8e0e62ca-d3b8-4159-bc19-37a87c3a7418 (old id 4613886)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/25156858?dopt=Abstract
date added to LUP
2016-04-01 10:33:06
date last changed
2022-02-10 03:18:42
@article{8e0e62ca-d3b8-4159-bc19-37a87c3a7418,
  abstract     = {{Dabigatran etexilate, a pro-drug of a direct thrombin inhibitor, was approved a few years ago for non-valvular atrial fibrillation and deep venous thrombosis. Rapid monitoring of the dabigatran level is essential in trauma and bleeding patients but the traditional plasma-based assays may not sufficiently display the effect. Furthermore, no antidote exists and reversal of the anticoagulant effect is impossible or difficult. The present study investigated the in vitro effect of dabigatran on whole blood thromboelastography (TEG) and its reversal by recombinant activated factor VII and prothrombin complex concentrate.}},
  author       = {{Solbeck, Sacha and Meyer, Martin A S and Johansson, Pär I and Meyer, Anna Sina P and Cotton, Bryan A and Stensballe, Jakob and Schött, Ulf and Ostrowski, Sisse R}},
  issn         = {{0167-5273}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{794--799}},
  publisher    = {{Elsevier}},
  series       = {{International Journal of Cardiology}},
  title        = {{Monitoring of dabigatran anticoagulation and its reversal in vitro by thrombelastography.}},
  url          = {{https://lup.lub.lu.se/search/files/15812578/1936263.pdf}},
  doi          = {{10.1016/j.ijcard.2014.07.084}},
  volume       = {{176}},
  year         = {{2014}},
}